FDA Drug Recalls

Recalls / Class II

Class IID-0191-2024

Product

Metoprolol Succinate Extended-Release Tablets, USP, 50 mg, 1000 Tablets, Rx Only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454. NDC: 45963-676-96

Brand name
Metoprolol Succinate
Generic name
Metoprolol Succinate
Active ingredient
Metoprolol Succinate
Route
Oral
NDCs
45963-676, 45963-709, 45963-677, 45963-678
FDA application
ANDA204161
Affected lot / code info
Batch 2447J211

Why it was recalled

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Recalling firm

Firm
CARDINAL HEALTHCARE
Manufacturer
Actavis Pharma, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
7200 Cardinal Pl W, Dublin, Ohio 43017-1094

Distribution

Quantity
1 unit
Distribution pattern
Nationwide USA

Timeline

Recall initiated
2022-01-26
FDA classified
2023-12-26
Posted by FDA
2024-01-03
Terminated
2024-09-29
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0191-2024. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Metoprolol Succinate · FDA Drug Recalls